Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

URGN vs ELTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

URGN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

URGN Overall Winner 6-Pillar Tally: URGN 3 – 2 ELTX (1 Tie) Matrix Metrics: URGN 7 – 3 ELTX

As of Nov 20, 2026, UroGen Pharma Ltd. (URGN) is the stronger overall head-to-head candidate over Elicio Therapeutics, Inc. (ELTX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). URGN carries a Unified Composite Score of 62.7/100 (BUY) at $27.65 (11.1x Forward P/E, -12.4% operating margin), whereas ELTX carries 53.1/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: URGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.8); meanwhile ELTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About URGN vs ELTX
URGN NASDAQ Head-to-Head Winner
UroGen Pharma Ltd. Ordinary Shares
Pharmaceutical Preparations
$27.65
-12.86% 1D
Market Cap $1.5B
TTM Revenue $250M
Forward P/E 11.1x
Beta / 30D Vol 1.24β · 90% Vol
Unified Composite Score
62.7 / 100 BUY
Tech 58.0 Fund 59.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.1%), weak momentum, RSI 40
RSI-14: 39.8 · SMA20: $29.67 · SMA50: $35.60
ELTX NASDAQ
Elicio Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-3.33% 1D
Market Cap $42.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.41β · 92% Vol
Unified Composite Score
53.1 / 100 HOLD
Tech 72.0 Fund 60.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.9%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $1.59 · SMA50: $1.74

6-Pillar Scorecard Institutional Category Breakdown (URGN 3 – 2 ELTX)

Columns: Metric · URGN · ELTX
1. Valuation Multiples URGN
Forward P/E 11.1x N/M
Trailing P/E 14.6x N/M
PEG Ratio N/M N/M
EV / Revenue 6.6x N/M
2. Growth & Scale URGN
Revenue Growth (YoY) +223.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $250M N/A
Market Cap $1.5B $42.5M
3. Profitability & Quality ELTX
Gross Margin 91.4% N/A
Operating Margin -12.4% 0.0%
Net Profit Margin -26.3% 0.0%
Return on Equity (ROE) -1481.3% -315.3%
4. Balance Sheet & Cash Flow ELTX
Cash Generation (TTM) -$132M -$38M
Cash Flow Margin -52.8% N/A
Net Cash / Leverage $111M Net Debt $9.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning URGN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 109.4% (10th %ile) 76.3% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: URGN (7) vs ELTX (3)
Institutional Metric URGN ELTX Criterion Row Edge
Market Capitalization
Scale
$1.5B $42.5M Larger Scale URGN
Trailing P/E Ratio
Valuation
14.6x N/M Lower Multiple URGN
Forward P/E Ratio
Valuation
11.1x N/M Lower Multiple URGN
Revenue Growth (YoY)
Growth
+223.9% +0.0% Higher Growth URGN
Operating Margin (TTM)
Profitability
-12.4% 0.0% Higher Margin ELTX
Net Profit Margin
Profitability
-26.3% 0.0% Higher Margin ELTX
Return on Equity (ROE)
Capital Efficiency
-1481.3% -315.3% Higher ROE ELTX
52-Week Range Position
Momentum
32% ($16–$51) 1% ($1–$16) Stronger Trend URGN
Beta / 30D Volatility
Risk Regime
1.24β · 90% Vol 0.41β · 92% Vol Lower Realized Risk URGN
Unified Institutional Score
Composite Signal
62.7 / 100 (BUY) 53.1 / 100 (HOLD) Higher Composite URGN
Trailing 12M Revenue (USD)
Operating Scale
$250M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
91.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$132M ($111M Net Debt) -$38M ($9.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon URGN +3.92 pp
URGN: -21.34% · ELTX: -25.26%
3M Horizon URGN +11.24 pp
URGN: -40.1% · ELTX: -51.34%
6M Horizon URGN +81.14 pp
URGN: -4.29% · ELTX: -85.43%
1Y Horizon URGN +91.52 pp
URGN: +9.42% · ELTX: -82.1%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period URGN Revenue ELTX Revenue URGN Op. Margin ELTX Op. Margin Margin Leader
FY2018 $0M N/A -6842.2% N/A URGN
FY2019 $0M N/A -608211.1% N/A URGN
FY2020 $10M $0M -1074.2% -1919.2% URGN
FY2021 $50M $30M -192.1% -138.8% ELTX
FY2022 $60M $0M -122.8% -1031.4% URGN
FY2023 $80M N/A -79.2% N/A URGN
FY2024 $90M N/A -107.1% N/A URGN
FY2025 $110M N/A -113.7% N/A URGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
URGN CONSOLIDATION
100d in phase · OBV ACCUMULATION
Current IV 109.4%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact URGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ELTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.3%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ELTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
URGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -12.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ELTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $42.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ URGN vs ELTX Key Questions & Quantitative Answers

As of Nov 20, 2026, UroGen Pharma Ltd. (URGN) is the stronger overall head-to-head candidate over Elicio Therapeutics, Inc. (ELTX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). URGN carries a Unified Composite Score of 62.7/100 (BUY) at $27.65 (11.1x Forward P/E, -12.4% operating margin), whereas ELTX carries 53.1/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: URGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.8); meanwhile ELTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

URGN leads the Growth & Scale pillar: URGN posts +223.9% YoY revenue growth and +0.0% YoY earnings growth on $250M TTM revenue (91.4% gross margin, -12.4% operating margin), compared with ELTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), URGN cumulative revenue shifted +1000.0% while ELTX shifted N/A. In operating R&D and SG&A reinvestment, URGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ELTX.

URGN screens cheaper on headline valuation multiples. URGN trades at 11.1x Forward P/E, 14.6x Trailing P/E, N/M PEG, and 6.6x EV/Revenue (-52.8% FCF margin), whereas ELTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against URGN (-1481.3% ROE) versus ELTX (-315.3% ROE) capital efficiency.

In options market volatility and institutional positioning, URGN carries 109.4% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.24β · 90% Vol realized risk). By comparison, ELTX carries 76.3% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.41β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.